Atos was recently selected by GCS AURAGEN to provide and orchestrate the high-performance computing infrastructure and storage of a new genomic pilot platform for high-flow sequencing calculation. As part of the French national plan for Genomic Science, Atos will manage this project together with its partners and co-contractors EOLAS and A2COM, which manage the hosting and outsourcing of health data respectively.
The objective of this national plan is to integrate the sequencing of individual genomes into a “care pathway” to enable personalized diagnostic and therapeutic management of patients. Initially, it will mainly concern people suffering from cancer and rare diseases for whom new therapeutic strategies may be proposed according to the genetic variations identified.
The Atos solution is designed to support the entire life cycle of genomic data – from DNA sequencing to analysis production. To develop an architecture that is as close as possible to the needs of the health ecosystem, Atos has brought together multiple business expertise (to share with biologists, geneticists and bioinformaticians) and technical expertise (in order to carry out dimensioning, comparative analysis, storage, archiving as well as a high-speed network).
This architecture is mainly based on a Dell EMC technology infrastructure that meets the project’s storage, performance, and scalability challenges (2.5 Petabytes of data per year over time). Atos, together with its partners EOLAS and A2COM, guarantees data hosting on a certified HDS (Health Data Hosting) site, and operates and maintains the entire platform for GCS AURAGEN.
Atos has been supporting the processing of genomic data for several years now, as shown by its long-term partnership with the Spanish National Centre for Genomic Analysis (CNAG-CRG), which has chosen Atos for its large-scale sequencing and DNA analysis work.
This contract reflects Atos’ strategic positioning in the health and life sciences sector, illustrated by its European and global client base, its close work with the health ecosystem, and its participation in major research projects such as Elixir, EIT Health, and CompBioMed.
